Trial Profile
A prospective study of a split-virion trivalent influenza vaccine assessing immunogenicity, safety, and tolerability in already primed children aged 3–14 years with documented overweight or obesity and in healthy controls.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- 01 Dec 2015 New trial record
- 19 Nov 2015 Results published in the Vaccine